Challenges in
computerized systems validation
Challenges in Computerized Systems Validation (CSV)
In the life sciences sector, digital transformation and the increasing adoption of computerized technologies have changed the way products are designed, manufactured, tested, and distributed. Computerized systems (CS) are omnipresent: production management, document management, preclinical and clinical trial tracking, analytical systems, connected systems… All of these elements have become critical to ensuring the quality of pharmaceutical, biotechnological, or medical device products.
However, this growing reliance on CS highlights a major challenge: ensuring and demonstrating the proper use and management of these computerized systems, including data integrity.
The process to achieve this is Computerized Systems Validation (CSV), essential to ensure compliance with quality, regulatory, and safety requirements.
When validation is poorly executed, consequences can be severe: regulatory warnings (warning letters), business losses, and—most importantly—risks to patient safety.
However, this growing reliance on CS highlights a major challenge: ensuring and demonstrating the proper use and management of these computerized systems, including data integrity.
The process to achieve this is Computerized Systems Validation (CSV), essential to ensure compliance with quality, regulatory, and safety requirements.
When validation is poorly executed, consequences can be severe: regulatory warnings (warning letters), business losses, and—most importantly—risks to patient safety.
Regulatory obligations recap
In the life sciences, computerized systems used to generate, record, process, transfer, and store critical data must comply with general and specific regulations.
Common requirements across all these regulations include identifying critical computerized systems and implementing the full initial and ongoing validation process, with the level of effort proportional to risk. (See details in the chapter “Regulatory Requirements for Computerized Systems Validation”). Validation must therefore demonstrate that risks are under control.
Regulations may vary depending on geographic region and specific sector. Variations usually concern the level of detail or the methodologies used, while the objectives to achieve remain the same.
Overview of regulatory texts by region (Europe / USA) and activity sectors
| Computerized Systems and Data / Sector | Europe (EU) | USA |
|---|---|---|
| Preclinical Studies / R&D Labs (chemicals & pharmaceuticals in in vitro and in vivo studies) | – OECD GLP (Good Laboratory Practices) – Directives 2004/9/EC and 2004/10/EC |
– 21 CFR Part 58 (GLP) |
| Clinical Studies / R&D Labs (investigational products – clinical study framework) | – GCP (Good Clinical Practices, per ICH E6) – EU Regulation 536/2014, effective Jan 2022 |
– ICH E6 (GCP) – 21 CFR Part 50 (Subject Protection) – 21 CFR Part 56 (IRB) |
| Drug and Active Substance Production (clinical trial and commercial products) | – EU GMP (Part I: GMP / Part II: Active Substance GMP / Part III: ICH Q9-Q10 / Part IV: GMP for ATMPs) | – 21 CFR Part 210-211 (cGMP) – ICH Q7 (GMP for APIs) |
| Drug and Product Distribution (clinical trial and commercial products) | – GDP (Good Distribution Practices – EU Guidelines 2013/C343/01) | – No strict regulatory equivalent in the USA; see 21 CFR Part 210-211 |
| Medical Device Production | – EU MDR 2017/745 & IVDR 2017/746 – ISO 13485:2016 (Quality Management for MD) |
– 21 CFR Part 820 (QSR) – 21 CFR Part 800+ (MD rules) |
| Medical Analysis Laboratories | – ISO 15189:2022 (Accreditation for medical laboratories – international standard) | – CLIA (Clinical Laboratory Improvement Amendments) |
| Cross-cutting Requirements ** (computerized systems & data management) | – EU GMP Annex 11: CS management & IT infrastructure – Annex 15: Qualification / Validation – AI Act (EU): first global legislative framework for AI, effective Aug 1, 2024 (phased implementation) |
– 21 CFR Part 11 (Electronic Records / Electronic Signatures) |
* Not all cited texts are legally binding. Some are guidelines or standards widely adopted in inspections but not strictly mandatory unless incorporated into local regulations.
** For computerized systems and data management, the US approach is fully cross-cutting via Part 11, while Europe has sector-specific texts.
Overview of guidelines by activity sector and applicability
| Text / Document | Type / Scope / Applicability | Enforceability / Use |
|---|---|---|
| GAMP 5 – Second Edition | Technical Guide (ISPE) / International / Pharmaceutical & more | Not legally binding, but widely used as an audit reference for CSV in GxP environments |
| ISO / TR 80002-1 (2009) – Part 1 | Technical Recommendation (ISO) / International / MD software validation | Not legally binding; guidance on ISO 14971:2007 risk management application for MD software, referencing IEC 62304:2006 |
| ISO / TR 80002-2 (2017) – Part 2 | Technical Recommendation (ISO) / International / MD quality system software validation (ERP/GED etc.) | Not legally binding; helps demonstrate software compliance in regulated MD context, positioning validation within full system testing |
| OECD No.17 (2016) & Supplement 1 (2023) | Consensus Documents / International – Member States / GLP | Non-binding; guidance for GLP application including cloud systems, data integrity |
| EU GMP Q&A on CSV (2023) | FAQ (EMA) / Regional (Europe) / Pharmaceutical | Non-binding; clarifies Annex 11 application |
| FDA CSA (Draft Guide, 2022) | Technical Guide (FDA) / Local (USA) | Non-binding; draft phase for future CSV inspections |
| FDA Considerations for AI (Jan 2025) | Technical Guide (FDA) | Non-binding; still under public comment |
Includes full testing on data integrity using ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available).
Challenge #1 – Ensuring patient safety
Errors, loss, or data falsification can result in non-compliant products, incorrect patient deliveries, diagnostic errors, untraceable audit decisions, or confidential data leaks.
Data can affect product quality, preclinical/clinical study outcomes, QC tests, or distribution. They are handled by increasingly complex computerized systems that must be controlled both internally and externally.
The core goal: safeguard patient health via proper CSV of critical data systems.
Data can affect product quality, preclinical/clinical study outcomes, QC tests, or distribution. They are handled by increasingly complex computerized systems that must be controlled both internally and externally.
The core goal: safeguard patient health via proper CSV of critical data systems.
Patient safety and regulatory authority information
Example for Medical Devices: 15–20% of safety notices (late 2024 / early 2025) required software upgrades due to validation deficiencies, showing CSV failures before deployment.
Challenge #2 – Costs arising from non-conformities
Skipping rigorous CSV may seem cost-saving but can cause far higher financial consequences: regulatory fines, product recalls, market losses, and project overruns. Proper CSV is thus a long-term cost management tool.
Costs from defective CSV
- Internal Control Example: A European company recalled an entire medical device lot due to poor QC software testing. Consequences: logistic costs, temporary CE suspension, doubled remediation validation costs.
- Inspection Example: 2024, an Indian pharma received a FDA Warning Letter for missing audit trail controls and user access management, causing product approval delays and import embargoes.
- Implementation Project Example: Inadequate validation methodology and resistance to change led to programming corrections, retraining, repeated testing, and an 18-month deployment delay, multiplying costs by four.
Challenge #3 – Managing compliance in complex technological environments
Emerging technologies (Cloud, AI, IoT) require updated CSV strategies.
Cloud-managed systems
Risk analysis must precede service delegation. SLA contracts define responsibilities, and supplier audits verify data center integrity, security, and compliance.
AI systems
AI validation must follow standard principles with specific risk analysis. Independent, diverse test datasets are required; changes in algorithms or training data are controlled within continuous validation. Cybersecurity must also be integrated.
Connected systems
IoT compliance requires full data flow management, encryption, signature verification, and continuous monitoring to ensure regulatory adherence and data security.
How to ensure system security and reliability
Early understanding of system use and technology, coupled with risk-based decision-making, is key.
Building a validation methodology
• Design reviews to ensure system configuration meets user needs
• Rigorous, documented testing covering all system lifecycle phases: Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ), in addition to development verification tests
• Tools for tracking anomalies and corrective actions to maintain configuration management and version control
• Periodic reviews including audit trail inspections to prevent regressions or negative impacts over time from software, data, or environment changes
Best practices also include close collaboration between project, quality, validation, and IT teams to avoid organizational silos. Validation activities should be integrated into the project timeline to implement validation as early as possible.
• Rigorous, documented testing covering all system lifecycle phases: Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ), in addition to development verification tests
• Tools for tracking anomalies and corrective actions to maintain configuration management and version control
• Periodic reviews including audit trail inspections to prevent regressions or negative impacts over time from software, data, or environment changes
Best practices also include close collaboration between project, quality, validation, and IT teams to avoid organizational silos. Validation activities should be integrated into the project timeline to implement validation as early as possible.
Continuously updating Computerized System Validation documents
Systems evolve, so validation must be continuous:
• Update protocols and SOPs to reflect new regulatory or technological requirements
• Maintain all validation test protocols and records for every system update (new versions, patches, added software, new usage environments, reference data modifications), considering the impact on identified risks
• Regularly review audit trails and system changes to ensure compliance with established quality procedures
Note: An incomplete or neglected audit trail is one of the most frequent observations during regulatory inspections.
• Update protocols and SOPs to reflect new regulatory or technological requirements
• Maintain all validation test protocols and records for every system update (new versions, patches, added software, new usage environments, reference data modifications), considering the impact on identified risks
• Regularly review audit trails and system changes to ensure compliance with established quality procedures
Note: An incomplete or neglected audit trail is one of the most frequent observations during regulatory inspections.
Efor Group supports you
At Efor Group, we understand the complex challenges life sciences companies face in validating their computerized systems.
Our services include:
• Experts in CSV aligned with international standards
• Remediation plans following audits or inspections
• Guidance on validation strategy and cost management
• Full project support in complex technological environments, including methodology implementation, critical risk identification and prioritization, validation documentation, and continuous updates
Conclusion: Computerized systems play a key role in life sciences, and their validation is essential to ensure patient safety, regulatory compliance, and business continuity. Efor Group is here to guide and support you at every stage, according to your needs.
Our services include:
• Experts in CSV aligned with international standards
• Remediation plans following audits or inspections
• Guidance on validation strategy and cost management
• Full project support in complex technological environments, including methodology implementation, critical risk identification and prioritization, validation documentation, and continuous updates
Conclusion: Computerized systems play a key role in life sciences, and their validation is essential to ensure patient safety, regulatory compliance, and business continuity. Efor Group is here to guide and support you at every stage, according to your needs.